CHMP

Genzyme MS portfolio clears two hurdles abroad

By

An EU regulatory body issued opinions that bode well for Lemtrada and Aubagio, and may positively impact other drugs in the category.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.